Buscar
Mostrando ítems 1-6 de 6
An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms
(Elsevier, 2019-02-06)
[Abstract] BACKGROUND. We previously reported a microarray-based diagnostic system for heart transplant endomyocardial biopsies (EMBs), using either 3-archetype (3AA) or 4-archetype (4AA) unsupervised algorithms to estimate ...
Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes
(Elsevier, 2021-08-04)
[Abstract] Background: The Molecular Microscope (MMDx) system classifies heart transplant endomyocardial biopsies as No-rejection (NR), Early-injury, T cell-mediated (TCMR), antibody-mediated (ABMR), mixed, and possible ...
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: GALACTIC‐HF Baseline Characteristics and Comparison With Contemporary Clinical Trials
(Willey Online Library, 2020-09-20)
[Abstract]
Aims
The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach ...
Molecular states associated with dysfunction and graft loss in heart transplants
(Elsevier, 2023-11-30)
[Abstract]
Background: We explored the changes in gene expression correlating with dysfunction and graft failure in endomyocardial biopsies.
Methods: Genome-wide microarrays (19,462 genes) were used to define mRNA ...
Redefining the molecular rejection states in 3230 heart transplant biopsies: relationships to parenchymal injury and graft survival
(Elsevier, 2024-03-26)
[Abstract] The first-generation Molecular Microscope (MMDx) system for heart transplant endomyocardial biopsies used expression of rejection-associated transcripts (RATs) to diagnose not only T cell-mediated rejection ...
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure
(Massachusetts Medical Society, 2020-11-13)
[Abstract]
BACKGROUND.
The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction.
Its effect on cardiovascular ...